May 24 |
Insider Sale at Madrigal Pharmaceuticals Inc (MDGL): Senior VP, Chief Pharmaceutical ...
|
May 21 |
Is Madrigal Pharmaceuticals Stock a Buy?
|
May 17 |
3 High Insider Ownership US Stocks With Up To 55% Revenue Growth
|
May 16 |
John Paulson's Strategic Moves in Q1 2024 Highlight Madrigal Pharmaceuticals' Prominent Role
|
May 8 |
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call Transcript
|
May 8 |
Madrigal Pharmaceuticals Inc (MDGL) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
|
May 7 |
Madrigal Pharmaceuticals (MDGL) Q1 2024 Earnings Call Transcript
|
May 7 |
Madrigal sees ‘tremendous interest’ in new NASH drug Rezdiffra
|
May 7 |
Madrigal Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Rezdiffra Launch
|
May 7 |
Madrigal Pharmaceuticals GAAP EPS of -$7.38 misses by $1.18
|